Abstrak RSS

Comparison Laser and Combine Laser Bevacizumab in Macular edema due to CRVO

Comparison Laser and Combine Laser Bevacizumab in Macular edema due to CRVO
Arief Kartasasmita, Siska Takarai, Astriviani Switania, Sutarya Enus
Universitas Padjadjaran, Presented on Japan Ophthalmological Society 2016
Bahasa Inggris
Universitas Padjadjaran, Presented on Japan Ophthalmological Society 2016
, ,

Background: laser photocoagulation is a still standard care for Central Retinal Vein Occlussion (CRVO) with macular edema.. However, visual acquity is rarely improve with laser photocoagulation. Vascular endothelial growth factor (VEGF) is known as important factor to macular edema due to CRVO. One possible approach to treat CRVO is to inhibit VEGF activity by Bevacizumab, an anti- VEGF antibody. Purpose: This study is a comparative prospective study to laser photocoagulation versus bevacizumab with laser treatment of macular edema secondary CRVO. Methods:Patients with macular edema secondary to CRVO was assigned in to two group. One group had a laser theraphy alone, the second group had laser therapy combining with bevacizumab intravitreal. Complete ophthalmologic examinations were performed just before treatment and one month after treatment. Changes in the logarithm of minimum angle of resolution (logMAR) visual acuity and central macular thickness is shown by optical coherence tomography (OCT). Result: Nineteen patients was inclused on this study, combination laser photocoagulation and intravitreal bevacizumab revealed a significantly better visual acuity compared with laser photocoagulation treatment (0.35 versus 0.13 logMAR; p 0.041) and reduced macular thickness 120,33µm versus 71,50µm (p 0,277), although this was not significant. Conclusion: intravitreal bevacizumab has a substantial effect on laser photocoagulation in increasing visual acuity of macular edema patients associated with CRVO.

Download: .Full Papers